A Meta-Analysis and Systematic Review on the Use of Adipose-Derived Mesenchymal Stem Cells for Knee Osteoarthritis Management.

BACKGROUND

Knee osteoarthritis (KOA) is one of the most common forms of joint degeneration, frequently resulting in persistent pain, reduced mobility, and impaired quality of life. The disease is characterized by the progressive breakdown of articular cartilage, synovial inflammation, and subchondral bone changes. Conventional management options such as analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroid injections, and surgical procedures are primarily aimed at alleviating symptoms rather than reversing or halting disease progression. In recent years, interest has grown in regenerative strategies, particularly the use of human adipose-derived mesenchymal stem cells (hAD-MSCs), due to their ability to modulate inflammation, promote tissue repair, and potentially regenerate damaged cartilage. These stem cells are favored for their ease of harvest, high yield, and ability to differentiate into chondrocytes. Despite their promising biological properties, the clinical benefit of intra-articular hAD-MSC therapy in KOA remains a subject of ongoing investigation, with varying outcomes reported across studies.

AIM

This systematic review and meta-analysis aims to assess the therapeutic efficacy of intra-articular hAD-MSC injections in individuals with knee osteoarthritis by analyzing data from randomized controlled trials.

METHODS

An extensive search of the literature was performed in alignment with the PRISMA framework, using four major databases: PubMed, Scopus, Web of Science, and the Cochrane Library. Studies considered for inclusion were randomized controlled trials (RCTs) examining the effects of intra-articular human adipose-derived mesenchymal stem cell (hAD-MSC) therapy in individuals diagnosed with knee osteoarthritis (KOA). Risk of bias in the selected trials was evaluated using the Cochrane Risk of Bias 2 (ROB2) tool. Statistical pooling of data was conducted using a random-effects model via Review Manager (RevMan) version 5.3.

RESULTS

A total of 11 RCTs, encompassing 510 patients, met the eligibility criteria for inclusion in the meta-analysis. Treatment with hAD-MSCs led to statistically significant improvements in WOMAC scores (mean difference [MD] =  - 25.32, 95% confidence interval [CI]  - 31.30 to  - 19.34;  < 0.00001) and VAS pain ratings (MD =  - 3.45, 95% CI  - 3.74 to  - 3.15;  < 0.00001). Furthermore, patient-reported quality of life showed meaningful enhancement following treatment (MD = 18.28, 95% CI 10.35-26.21;  < 0.00001). However, analysis of KOOS-Symptom domain scores did not show a statistically significant difference. The degree of heterogeneity differed between outcome measures.

CONCLUSION

This meta-analysis demonstrates that intra-articular administration of hAD-MSCs can effectively reduce pain and enhance joint function and quality of life in patients with knee osteoarthritis. These results support the potential of hAD-MSCs as a regenerative and disease-modifying therapeutic approach. Nevertheless, additional well-designed clinical trials are necessary to establish long-term safety and sustained clinical benefits.